Biotechnology

Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

December 10, 2020 12:50 AM

FRAMINGHAM, MA / ACCESSWIRE / December 10, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that it has entered into a securities purchase agreement with several institutional and accredited investors providing for the purchase and sale of...

Read more

Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology

December 9, 2020 8:35 AM

Xenetic leverages its proprietary drug delivery platform, PolyXen, through partnerships with biotechnology and pharmaceutical companies to improve the half-life and other pharmacological properties of next-generation biologic drugs Epolong, a polysialylated form of recombinant human erythropoietin that leverages PolyXen, has been shown to be effective and generally well tolerated in Pharmsynthez-conducted trial as a treatment for anemia in...

Read more

Dyadic to Interview with FOX Business Network on Wednesday December 9, 2020

December 9, 2020 8:30 AM

JUPITER, FL / ACCESSWIRE / December 9, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more

Babe Ruth League Partners With Binovi Technologies in Order to Provide Sport Vision Training to Its Youth Athletes

December 9, 2020 3:05 AM

TORONTO, ON / ACCESSWIRE / December 9, 2020 / Binovi Technologies Corp. (Binovi) (TSXV:VISN)(OTCQB:BNVIF)(FRA:2EYA) is proud to announce a partnership with the Babe Ruth League, one of the largest youth baseball and softball organizations in the United States, serving more than 1,000,000 players in over 11,000 leagues across the country. Through the partnership, Binovi becomes the Official Provider of Health Programming for Babe Ruth League,...

Read more

Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment

December 8, 2020 8:30 AM

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / December 8, 2020 / December 2, 2020 / Pascal Biosciences Inc. (TSXV:PAS)(OTC PINK:BIMUF) ("Pascal" or the "Company") and SōRSE Technology Corporation ("SōRSE") have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the cannabinoid PAS-393 towards clinical testing against cancer. "This progress is very promising because this step is critical for...

Read more

GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations

December 8, 2020 8:00 AM

LAS VEGAS / ACCESSWIRE / December 8, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,857,107 entitled "Cannabinoid-Containing Complex Mixtures for the Treatment of Mast-Cell-Associated or Basophil-Mediated Inflammatory Disorders" today, Dec. 8, 2020. This U.S. patent is assigned to GBS Global Biopharma (GBS), Inc., GB Sciences' Canadian entity. GBS's new...

Read more

Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD

December 8, 2020 8:00 AM

Havn Life will collaborate on future clinical studies with Heroic Hearts Project to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD). VANCOUVER, BC / ACCESSWIRE / December 8, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural...

Read more

Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020

December 7, 2020 10:02 AM

Preliminary safety and efficacy data from Phase 1b firstMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) presented today Also presented today: Long-term subgroup analyses from L-MIND study evaluating tafasitamab combined with lenalidomide in patients with relapsed or refractory DLBCL PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / December 7, 2020 / MorphoSys AG (FSE:MOR; Prime Standard Segment;...

Read more

Experion Provides Fiscal 2020 Update

December 7, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / December 7, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to provide an update from the CEO regarding the Company's strategic and operational execution highlights to date for fiscal 2020. Key Comments on our Strategic Execution The last four quarters have been a transformational period for Experion. Early this year, we embarked on a mission to...

Read more

Apollo Endosurgery Extends Maturity Date on Senior Secured Term Loan and Convertible Notes

December 7, 2020 8:30 AM

AUSTIN, TX / ACCESSWIRE / December 7, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced an agreement with Solar Capital Ltd. to extend the interest only period and maturity date of its existing term loan. In addition, the Company and holders of 99.25% of the outstanding principal amount of its 6% convertible notes due 2024 have...

Read more

Edesa Biotech Reports Fiscal Year 2020 Results

December 7, 2020 7:45 AM

TORONTO, ON / ACCESSWIRE / December 7, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the fiscal year ended September 30, 2020 and provided an update on its business. During the fiscal year, Edesa added two Phase 2-ready biologics to its development pipeline, with a focus on COVID-19 and other strategic indications. Last month, the company initiated a Phase 2/Phase 3...

Read more

Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences

December 7, 2020 6:45 AM

-Benzinga Global Small Cap Conference on December 8th -LD Micro Main Event on Dec 15th -H.C. Wainwright BioConnect, held on Jan 11-14 -Virtual Biotech Showcase, held on Jan 11-14 KELOWNA, BC / ACCESSWIRE / December 7, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced today that its Chairman & CEO Chris Bunka is scheduled to present at four upcoming...

Read more

Tetra Bio-Pharma Provides Update on Market Potential for QIXLEEF(TM)

December 7, 2020 6:30 AM

Tetra Estimates Net Sales reaching $675M USD by 2027 Tetra is evaluating potential commercial partners to launch QIXLEEF™ in USA OTTAWA, ON / ACCESSWIRE / December 7, 2020 /  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today provided an update on the potential US market for QIXLEEF™, a botanical cannabinoid-derived medicine that meets USA cGMP...

Read more

Helix BioPharma Corp. Closes Private Placement

December 4, 2020 8:30 PM

RICHMOND HILL, ON / ACCESSWIRE / December 4, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $1,100,000. The terms of the placement are for the purchase of units at $0.50 per unit....

Read more

Wuhan General Group Financials Update

December 4, 2020 10:20 AM

CAPE TOWN, SA / ACCESSWIRE / December 4, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update to its shareholders: The Company is pleased to inform its shareholders that with OTCIQ having just granted access to the platform, it has started the process of updating its profile...

Read more

Havn Life Sciences Partners With Veterans Mental Health Non-Profit, Westwood Institute

December 3, 2020 8:00 AM

Westwood Institute Founder, Dr. Marvin Westwood Will Work With Havn Life's Research Team to Develop Best Practices for Combining Therapy and Psychedelic Interventions for Veterans VANCOUVER, BC / ACCESSWIRE / December 3, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive...

Read more

ContextVision Drives Medical Image Enhancement Innovation

December 2, 2020 3:45 PM

Medical Technology Software Company Celebrates Year of Product Expansion and Internal Growth STOCKHOLM / ACCESSWIRE / December 02, 2020 / ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announces a progressive year of product innovation and talent acquisition. The company will virtually display its latest advancements in image enhancement as well as introduce new key staff to...

Read more

Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board

December 2, 2020 11:45 AM

TUCSON, AZ/ ACCESSWIRE / December 2, 2020 / Aqualung Therapeutics, an early-stage biotech company developing an anti-inflammatory therapeutic platform for patients with serious unchecked inflammatory disease, has published proof of concept studies in EBio Medicine suggesting eNAMPT as a potential biomarker for the severity of invasive Prostate Cancer (PCa), and eNAMPT- neutralization as an effective therapeutic approach to limit PCa invasion and...

Read more

Molecular Partners to Share Clinical Data and Expanding Portfolio Strategy at Virtual R&D Day on December 17, 2020

December 2, 2020 11:45 AM

New data from clinical and preclinical oncology programs to be presented Preliminary Phase 1 data from anti-COVID-19 candidate MP0420 (ensovibep) expected ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 2, 2020 / Molecular Partners AG (SWX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it will host a virtual R&D Day for investors...

Read more

EV Biologics Signs Funding Agreement for Biotech Security Token Offering

December 2, 2020 8:00 AM

CHEYENNE, WY / ACCESSWIRE / December 2, 2020 / EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a funding agreement with an investment bank to sponsor the raise of $25-$50 million for research and development via a Security Token Offering "STO" - a worlds' first in Biotech. The Company will start this innovative blockchain funding program starting January 1, 2021 that will fund the research and development for Acute Lung...

Read more